| Date | Time | Source | |
| 06/17/2013 | 7:05AM | GLOBE | DaVita Labs and Myriad RBM Announce Biomarker Research Collaboration
SALT LAKE CITY, June 17, 2013 (GLOBE NEWSWIRE) -- DaVita Labs, a unit of DaVita HealthCare Partners Inc. (NYSE:DVA) and Myriad RBM, a wholly-owned subsidiary of Myriad Genetics (Nasdaq:MYGN) announced today a research collaboration to conduct protein biomarker discovery research with the goal of developing and commercializing... More...>> |
| 06/14/2013 | 10:06AM | ZACKS | Company News for June 14, 2013 - Corporate Summary
• Empire Co. announced it was purchasing Safeway Inc.’s (NYSE:SWY) Canadian assets for $5.7 billion, following which shares of the company surged 7.4% • Gannett Co., Inc. (NYSE:GCI) revealed its intentions of buying Belo Corp (NYSE:BLC) for $1.5 billion. Following this... More...>> |
| 06/13/2013 | 12:25PM | GLOBE | Supreme Court Upholds Myriad's cDNA Patent Claims
SALT LAKE CITY, June 13, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today said the Supreme Court of the United States upheld its patent claims on complementary DNA, or cDNA. However, the Court ruled that five of Myriad's claims covering isolated DNA were not patent eligible. Following today's decision... More...>> |
| 06/13/2013 | 11:20AM | DJN | High Court Rules Isolated Human Genes Can't Be Patented
The Supreme Court unanimously ruled Thursday that human genes isolated from the body can't be patented, a victory for doctors and patients who argued that such patents interfere with scientific research and the practice of medicine. The court was handing down one of its most significant rulings in the age of molecular... More...>> |
| 06/11/2013 | 7:05PM | ZACKS | Zimmer Stays at Neutral - Analyst Blog
We recently reiterated our Neutral recommendation on leading orthopedic medical devices company Zimmer Holdings (ZMH). While we hold a favorable view regarding the company’s gradually improving volume trend, several restructuring initiatives and diversion of savings for further investment, we remain concerned about... More...>> |
| 06/03/2013 | 7:00AM | GLOBE | Myriad Genetics to Present at the Goldman Sachs Global Healthcare Conference
SALT LAKE CITY, June 3, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Goldman Sachs 34th Annual Global Healthcare Conference, at 8:40 a.m. Pacific on June 11, 2013 at the Terranea Resort and Spa in Rancho Palos Verdes... More...>> |
| 06/01/2013 | 8:00AM | GLOBE | AstraZeneca Advances PARP Inhibitor Into Phase 3 Trial With BRACAnalysis(R)
SALT LAKE CITY, June 1, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that AstraZeneca will use Myriad's BRACAnalysis test as a companion diagnostic to stratify patients in AstraZeneca's pivotal Phase 3 clinical studies for olaparib. Myriad has submitted an Investigational Device Exemption... More...>> |
| 05/30/2013 | 7:00AM | GLOBE | Myriad Genetics to Present PROLARIS(R) Data at ASCO 2013, Continuing Its Commitment to Cancer Research
SALT LAKE CITY, May 30, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Jack Cuzick, Ph.D., of Queen Mary College University of London, will present data from five PROLARIS® clinical studies in patients with prostate cancer at the American Society of Clinical Oncology (ASCO) annual meeting... More...>> |
| 05/21/2013 | 3:20PM | ZACKS | QIAGEN Downgraded to Strong Sell - Analyst Blog
Zacks Investment Research downgraded QIAGEN N.V. (QGEN) to a Zacks Rank #5 (Strong Sell) on May 16. Why the Downgrade? Earnings momentum for this molecular diagnostics company has slumped following disappointing first-quarter 2013 results. Shares of QIAGEN have been on a downtrend since April 29, when it reported a weak... More...>> |
| 05/21/2013 | 11:00AM | ZACKS | FDA Nod for COV's Advanced Nellcor - Analyst Blog
International health care products major, Covidien plc (COV) has won the approval of the U.S. Food and Drug Administration (“FDA”) for its motion-tolerant Nellcor pulse oximetry devices. The system can effectively detect and diagnose acute and potentially fatal breathing difficulties at an early stage, thereby... More...>> |
| 05/17/2013 | 9:50AM | ZACKS | CE Mark for STJ's ILUMIEN OPTIS - Analyst Blog
Medical devices major, St. Jude Medical Inc. (STJ) has won CE Mark approval for its ILUMIEN OPTIS Percutaneous Coronary Intervention (PCI) Optimization System. This intravascular imaging technology is an advanced version of the company’s Ilumien System from the cardiovascular products portfolio, which is used to... More...>> |
| 05/17/2013 | 8:50AM | ZACKS | Stryker Reiterated at Neutral - Analyst Blog
On May 16, we retained Stryker Corp. (SYK) at Neutral, following its first-quarter results. Stryker’s reported solid sales in the U.S. but international markets, especially Europe, still remain weak. Why the Retention? On Apr 24, Stryker posted first-quarter 2013 adjusted earnings per share of... More...>> |
| 05/16/2013 | 12:00PM | ZACKS | SGEN's Adcetris under FDA Review - Analyst Blog
Seattle Genetics, Inc. (SGEN) recently announced that the US Food and Drug Administration (FDA) has accepted its supplemental biologics license application (sBLA) seeking approval of Adcetris (brentuximab vedotin) for an additional indication. The company is looking to get Adcetris approved for retreatment and extended... More...>> |
| 05/16/2013 | 5:10AM | ZACKS | Covidien Prices Senior Notes - Analyst Blog
Healthcare major, Covidien plc (COV) announced that its fully-owned subsidiary Covidien International Finance S.A. (CIFSA) will be offering 2.950% underwritten senior notes due 2023 for an aggregate purchase price of $750 million. The net proceeds will be used primarily to repay its earlier debt of 1.875% senior notes... More...>> |
| 05/15/2013 | 11:00AM | ZACKS | Much Awaited Test Launch by Genomic - Analyst Blog
Recently, Genomic Health Inc. (GHDX) made available its lead pipeline candidate Oncotype DX prostate cancer test to physicians and their patients. This comes as a major boost to the company as its effort to launch the test by the second quarter of 2013 (ending Jun 30, 2013) paid off. The launch of the prostate cancer... More...>> |
| 05/15/2013 | 10:30AM | ZACKS | Myriad Soars Higher on Celeb Clout - Analyst Blog
Shares of Myriad Genetics Inc. (MYGN) touched a new 52-week high of $34.70 on Tuesday, May 14, 2013 following news out of Hollywood. Academy Award winning Hollywood star Angelina Jolie had tested positive for a ‘faulty’ version of the BRCA1 gene, which is exclusively licensed with the company. Subsequently... More...>> |
| 05/14/2013 | 7:05AM | GLOBE | Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference
SALT LAKE CITY, May 14, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, president and CEO, is scheduled to present at the Bank Of America Merrill Lynch 2013 Health Care Conference, at 10:00 a.m. Pacific on May 16, 2013, at the Encore at the Wynn in Las Vegas, Nevada... More...>> |
| 05/13/2013 | 10:20AM | ZACKS | Genomic Gains Coverage for DCIS - Analyst Blog
Genomic Health Inc. (GHDX) continues to make strides towards establishing coverage for its Oncotype DX breast cancer test. The company disclosed that the assigned contractor for its Oncotype DX breast cancer test Palmetto GBA has expanded coverage policy for all eligible Medicare patients to include those for ductal carcinoma... More...>> |
| 05/13/2013 | 5:30AM | ZACKS | GHDX Reports Loss, Beats on Revs - Analyst Blog
Genomic Health (GHDX) reported first-quarter 2013 net loss of $0.9 million, down from a net income of $0.8 million in the year-ago period. The company’s reported loss of 3 cents per share was significantly down from the year-ago period’s earnings of 2 cents per share as well as the Zacks Consensus Estimate... More...>> |
| 05/13/2013 | 5:20AM | ZACKS | Earnings Beat for PETS, Margins Up - Analyst Blog
America’s largest pet pharmacy, PetMed Express (PETS) reported earnings of 23 cents per share in the fourth quarter of fiscal 2013, 2 cents ahead of the Zacks Consensus Estimate and up 15% year over year. Fiscal 2013 earnings per share were 86 cents, up 7.5% year over year. Net sales in the quarter were down 8.6... More...>> |
